Updated on 2025/06/25

写真a

 
Ayada Yoshiyuki
 
Organization
Faculty of Medicine, Dentistry and Pharmaceutical Sciences Assistant Professor
Position
Assistant Professor
External link

Research Interests

  • 病理

  • 骨軟部腫瘍

  • リンパ腫

Research Areas

  • Life Science / Human pathology

Education

  • 岡山大学大学院   医歯薬学総合研究科病理学(腫瘍病理)  

    2020.4 - 2024.3

      More details

  • Okayama University   医学部   医学科

    2012.4 - 2018.3

      More details

Research History

  • Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University   Department of Pathology and Oncology   Assistant Professor

    2025.4

      More details

  • 岡山大学病院   助教

    2024.4 - 2025.3

      More details

  • 岡山大学大学院医歯薬学総合研究科   博士課程-大学院生

    2020.4 - 2024.3

      More details

  • 香川県立中央病院   初期研修医

    2018.4 - 2020.3

      More details

Professional Memberships

 

Papers

  • Successful immunotherapy with ipilimumab and nivolumab in a patient with pulmonary sclerosing pneumocytoma. International journal

    Yumi Inukai-Motokura, Kiichiro Ninomiya, Takahiro Baba, Hiroki Omori, Tetsuya Takeguchi, Mari Uno, Yoshiyuki Ayada, Takehiro Tanaka, Yoshinobu Maeda, Kadoaki Ohashi

    International cancer conference journal   14 ( 1 )   60 - 63   2025.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pulmonary sclerosing pneumocytoma (PSP) is a rare form of lung cancer that occasionally presents with lymph node and extrapulmonary metastases, and multiple lesions. The treatment of metastatic PSP remains undefined. This study reports the case of a 48-year-old female patient diagnosed with PSP following surgical intervention for a solitary nodule in the left lower lobe. Four years later, recurrence occurred in the left hilar and mediastinal lymph nodes, necessitating an additional resection. Concurrently, sacral metastases developed and required palliative radiotherapy. Genetic analysis identified an AKT1 E17K mutation, characteristic of PSP, and absence of programmed cell death ligand 1 (PD-L1) expression in the tumor. Two years post-recurrence, the tumor recurred in the left mammary gland and mediastinal lymph nodes. Combination immunotherapy with ipilimumab and nivolumab yielded a significantly positive response in this metastatic PSP case. This is the first reported case of successful treatment of multiple distant metastatic PSP with ipilimumab and nivolumab, following the failure of various local treatments. Further case series are warranted to validate the efficacy of immunotherapy in metastatic PSP.

    DOI: 10.1007/s13691-024-00737-8

    PubMed

    researchmap

  • Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report. International journal

    Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, Yoshiyuki Ayada, Go Makimoto, Eiki Ichihara, Natsuko Okita, Shinichi Toyooka, Yoshinobu Maeda, Masahiro Tabata

    JCO precision oncology   8   e2400228   2024.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Imatinib may be a useful targeted agent for patients with advanced gastric adenocarcinoma who have KIT mutations.

    DOI: 10.1200/PO.24.00228

    PubMed

    researchmap

  • Kimura disease forming a human polyomavirus 6-negative parotid gland nodule with prominent squamous metaplasia in a young female: A case report. International journal

    Kenji Yorita, Tatsuya Fujii, Toshitaka Nagao, Ichiro Murakami, Yumiko Hashida, Tomonori Higuchi, Masanori Daibata, Makoto Toi, Yoshiyuki Ayada, Takuro Igawa

    Radiology case reports   18 ( 5 )   1933 - 1938   2023.5

     More details

    Language:English  

    A case of an asymptomatic 19-year-old woman with Kimura disease presenting with a nodule in the right parotid gland is presented. She had a medical history of atopic dermatitis and noticed a mass on her right-side neck. Cervical lymphadenopathy was clinically diagnosed. The initial management plan was to observe the lesion, which had enlarged from 1 cm to 2 cm in diameter 6 months later. An excisional biopsy was performed, and the pathology confirmed an eosinophil-containing inflammatory parotid gland lesion with many squamous nests and cysts, mimicking a parotid gland tumor. High serum immunoglobulin E levels, peripheral blood eosinophilia, and pathological and genetic diagnoses confirmed Kimura disease. The lesion tested negative for human polyomavirus 6. No recurrence was observed 15 months after the biopsy. The prognosis of Kimura disease without human polyomavirus 6 infection may be favorable; however, further validation of this hypothesis is required as only 5 or 6 cases of Kimura disease have been evaluated for this viral infection. Proliferative squamous metaplasia occurring in parotid gland lesions of Kimura disease is rare and may complicate the diagnostic imaging and pathological diagnosis.

    DOI: 10.1016/j.radcr.2023.02.027

    PubMed

    researchmap

  • Immunohistochemistry for IRTA1 and MNDA helps differentiate gastric MALT lymphoma from chronic gastritis/reactive lymphocyte hyperplasia.

    Yoshiyuki Ayada, Takuro Igawa, Yusuke Naoi, Kyosuke Horikawa, Tetsuya Tabata, Takehiro Tanaka, Tadashi Yoshino

    Journal of clinical and experimental hematopathology : JCEH   62 ( 4 )   195 - 201   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    It is difficult to histologically differentiate extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) from chronic gastritis (CG)/ reactive lymphoid hyperplasia (RLH). To determine whether immunohistochemistry for IRTA1 and MNDA can differentiate gastric MALT lymphoma from CG/RLH, we investigated 81 stomach biopsy specimens [Wotherspoon grade (WG) 1, 11 cases; WG 2, 9 cases; WG 3, 20 cases; WG 4, 31 cases; and WG 5, 10 cases]. According to a previously reported algorithm involving PCR for immunoglobulin heavy (IgH) chain locus rearrangement, all 81 cases were divided into three groups: CG/RLH (55 cases), MALT lymphoma (19 cases) groups, and IgH undetectable group (7 cases). We analyzed the CG/RLH and MALT lymphoma groups. The median percentage of IRTA1-positive cells was 0% (range 0%-90.6%) in the CG/RLH group and 43.5% (range 0%-97.6%) in the MALT lymphoma group (p < 0.0001). The median percentage of MNDA-positive cells was 32.4% (range 0%-97.6%) in the CG/RLH group and 55.1% (range 0%-97.6%) in the MALT lymphoma group (p = 0.0044). These results indicate that immunohistochemistry for IRTA1 and MNDA can help differentiate gastric MALT lymphoma from CG/RLH.

    DOI: 10.3960/jslrt.22021

    PubMed

    researchmap

  • Overexpression of folate receptor alpha is an independent prognostic factor for outcomes of pancreatic cancer patients.

    Shizuma Omote, Katsuyoshi Takata, Takehiro Tanaka, Tomoko Miyata-Takata, Yoshiyuki Ayada, Mai Noujima-Harada, Rika Omote, Tetsuya Tabata, Yasuharu Sato, Tatsuya Toyokawa, Hironari Kato, Takahito Yagi, Hiroyuki Okada, Tadashi Yoshino

    Medical molecular morphology   51 ( 4 )   237 - 243   2018.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Pancreatic cancer has a poor prognosis; hence, novel prognostic markers and effective therapeutic targets should be identified. We aimed to evaluate folate receptor alpha (FR-α) expression in pancreatic cancer and examine its association with clinicopathological features. We utilized tissue samples from 100 primary pancreatic cancer patients who underwent surgery. FR-α was expressed in 37 of 100 cases (37%). The FR-α-positive group (median, 18.8 months) had a significantly poorer prognosis than the FR-α-negative group [median 21.3 months; HR 1.89 (1.12-3.12); P = 0.017]. These groups were not significantly different regarding progression-free survival (P = 0.196). Furthermore, other serum tumor markers including CA19-9 (mean, 186 vs. 822 U/ml; P = 0.001), Dupan-2 (286 vs. 1133 U/ml; P = 0.000), and Span-1 (69.7 vs. 171.9 U/ml; P = 0.006) were significantly downregulated in the FR-α-positive group. CA19-9 was another prognostic factor, in addition to FR-α, and patient prognosis showed clear stratification curves with the expression of these two molecules. Along with CA19-9, FR-α expression was an independent prognostic factor for the overall survival. FR-α and CA19-9 helped predict patient prognosis based on stratification curves.

    DOI: 10.1007/s00795-018-0197-8

    PubMed

    researchmap

MISC

  • HAVCR2ホモ接合型変異を有し家族内発症した皮下脂肪織炎様T細胞リンパ腫

    植田 裕子, 藤井 伸治, 松原 千哲, 近藤 歌穂, 寺尾 俊紀, 松村 彰文, 清家 圭介, 藤原 英晃, 淺田 騰, 遠西 大輔, 藤井 敬子, 松岡 賢市, 森坂 広行, 綾田 善行, 吉野 正, 前田 嘉信

    臨床血液   65 ( 5 )   465 - 466   2024.5

     More details

    Language:Japanese   Publisher:(一社)日本血液学会-東京事務局  

    J-GLOBAL

    researchmap

  • Histological findings of gastric lesions in patients with PAH during administration of PGI2 Reviewed

    堀川恭佑, 田中健大, 荒島拓馬, 綾田善行, 小野早和子, 井川卓朗, 磯田哲也, 神農陽子, 万波智彦, 山元英崇

    日本病理学会会誌   113 ( 1 )   376 - 376   2024.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • An autopsy case of dedifferentiated chondrosarcoma with Triton-like histology and H3K27me3 loss

    綾田善行, 溝渕光一, 守都敏晃, 大原信哉, 小田義直, 山元英崇

    日本病理学会会誌   113 ( 1 )   443 - 443   2024.2

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 悪性Triton腫瘍様の組織像とH3K27me3発現消失を呈する脱分化軟骨肉腫の一剖検例 Reviewed

    綾田 善行, 溝渕 光一, 守都 敏晃, 大原 信哉, 小田 義直, 山元 英崇

    日本病理学会会誌   113 ( 1 )   443 - 443   2024.2

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    researchmap

  • 【がん遺伝子パネル検査と病理診断】症例提示 悪性骨巨細胞腫の遺伝子異常と組織像の関連

    山元 英崇, 石原 新, 岩崎 健, 綾田 善行, 溝渕 光一, 小田 義直

    病理と臨床   42 ( 1 )   0072 - 0075   2024.1

     More details

    Language:Japanese   Publisher:(株)文光堂  

    J-GLOBAL

    researchmap

  • Two cases of juvenile cerebral amyloid angiopathy with history of a infantile neurosurgery

    吉岡良介, 唐沢康暉, 西堂創, 平野雄大, 坂口雄亮, 竹信敦充, 寺岡暉, 綾田善行, 山元英崇, 本田裕之, 稲生靖, 保谷克巳

    小児の脳神経(Web)   49 ( 3 )   2024

  • KIT Q556_K558欠失変異を有する胃腺癌患者に対してイマチニブが著効した1例

    二宮貴一朗, 遠西大輔, 岡本邦夫, 安藤翠, 中村聡子, 冨田秀太, 綾田善行, 槇本剛, 市原英基, 沖田南都子, 豊岡伸一, 前田嘉信, 田端雅弘

    日本癌治療学会学術集会(Web)   62nd   2024

  • toxoplasmic lymphadenitis

    綾田善行, 佐藤康晴

    病理と臨床   41 ( 臨増 )   225 - 225   2023.4

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • Immunohistohemistory for IRTA1 and MNDA in differentiating gastric MALT lymphoma from CG/RLH.

    綾田善行, 井川卓朗, 堀川恭佑, 田端哲也, 田中健大, 吉野正

    日本病理学会会誌   112 ( 1 )   359 - 359   2023.3

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • A case of mucosal colon cancer with signet-ring cell carcinoma resected endoscopically.

    平松万尚, 平松万尚, 砂田光俊, 松尾泰治, 松尾恵輔, 日山亨, 綾田善行, 田中健大

    広島医学   75 ( 3 )   148 - 152   2022.3

     More details

    Language:Japanese  

    J-GLOBAL

    researchmap

  • 傍腫瘍性神経症候群の合併が疑われたホジキンリンパ腫の一例

    綾田 善行, 井川 卓朗, 田端 哲也, 田中 健大, 佐藤 康晴, 吉野 正

    日本リンパ網内系学会会誌   61   109 - 109   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本リンパ網内系学会  

    J-GLOBAL

    researchmap

  • 特異な病理像を呈した免疫チェックポイント阻害剤関連肝障害の1例

    綾田 善行, 筒井 朱美, 妹尾 知典, 永野 拓也, 高口 浩一, 大橋 龍一郎, 安藤 翠

    日本消化器病学会四国支部例会プログラム・抄録集   111回   75 - 75   2019.6

     More details

    Language:Japanese   Publisher:日本消化器病学会-四国支部  

    J-GLOBAL

    researchmap

  • 好酸性顆粒状胞体を有するXp11.2転座型腎細胞癌の一例

    綾田 善行, 安藤 翠, 中村 聡子, 黒田 直人, 溝渕 光一

    日本病理学会会誌   108 ( 1 )   466 - 466   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

  • 葉酸レセプターαは膵癌において高率に発現し予後不良な経過を示す

    綾田 善行, 平部 顕子, 加藤 光晴, 高田 尚良, 高田 友子, 佐藤 康晴, 柳井 広之, 吉野 正

    日本病理学会会誌   104 ( 1 )   516 - 516   2015.3

     More details

    Language:Japanese   Publisher:(一社)日本病理学会  

    J-GLOBAL

    researchmap

▼display all